- Home
- FUSB vs ACRV Comparison
FUSB vs ACRV Comparison
Compare FUSB & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FUSB | ACRV |
|---|---|---|
| Founded | 1952 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.8M | 82.7M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | FUSB | ACRV |
|---|---|---|
| Price | $13.53 | $2.38 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.67 |
| AVG Volume (30 Days) | 9.3K | ★ 449.4K |
| Earning Date | 01-26-2026 | 11-13-2025 |
| Dividend Yield | ★ 2.05% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.93 | N/A |
| Revenue | ★ $36,068,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $805.20 |
| P/E Ratio | $14.71 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.30 | $1.05 |
| 52 Week High | $14.79 | $8.00 |
Technical Indicators
Market Signals| Indicator | FUSB | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 49.66 | 51.54 |
| Support Level | $12.90 | $2.12 |
| Resistance Level | $13.71 | $2.44 |
| Average True Range (ATR) | 0.30 | 0.20 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 41.47 | 40.98 |
Price Performance
Historical ComparisonAbout FUSB First US Bancshares Inc.
First US Bancshares Inc is a bank holding company. The Bank conducts general commercial banking business and offers banking services such as demand, savings, individual retirement account and time deposits, personal and commercial loans, safe deposit box services, and remote deposit capture. The Bank provides a range of commercial banking services to small and medium-sized businesses, property managers, business executives, professionals, and other individuals.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.